Yibing Wu 

CEO of Temasek, China

Yibing Wu currently serves as CEO of Temasek in China. He joined Temasek in October 2013 and previously held roles including Joint Head, Technology & Consumer; Joint Head, Enterprise Development Group; and Joint Head, Portfolio Strategy & Risk Group.

As a global investment company headquartered in Singapore, Temasek looks at investments through the lens of key structural trends. As Joint Head, Technology & Consumer, Mr Wu led the team to focus on areas including digitisation of the industry chain and infrastructure, digital platforms, as well as emerging consumer trends and brands to shape a resilient portfolio.

Currently, he continues to lead Temasek’s teams in China to actively participate in China’s economic reform and development. China is one of the largest markets for Temasek’s investments, with the China portfolio currently forming 18% of Temasek's global portfolio for the financial year ending 31 March 2025.

Prior to joining Temasek, Mr Wu was President of CITIC Private Equity Funds Management, a position he held since December 2009. He concurrently served as Chairman and Chief Executive Officer of Goldstone Investment Co. Ltd.

Mr Wu began his career with McKinsey, rising to become Senior Partner and Head of Asia Pacific M&A Practice. He was also General Manager of McKinsey Beijing, where he was responsible for providing M&A, corporate restructuring and IPO advisory for large Chinese enterprises. He subsequently joined the Lenovo Group and led the acquisition and integration of the IBM PC business, serving as Chief Strategy Officer, Chief Integration Officer, Chief Transformation Officer/Chief Information Officer of Lenovo Group. He was later appointed to Lenovo parent Legend Holdings, as Executive Vice President responsible for the overall business operations and overseeing its direct investment business.

He also serves on the board of the China Social Entrepreneur Foundation.

Mr Wu holds a Doctor of Philosophy degree (PhD) in Biochemistry from Harvard University and a Bachelor of Science degree (BSc) in Molecular Biology from University of Science and Technology of China.